In March 2020, the World Health Organization declared a global COVID-19 pandemic and the UK announced a strict national lockdown. When Oxford University scientists were sent home, they rolled up their sleeves, switched on their computers and started to help develop new drugs to target SARS-CoV-2, the virus that causes COVID-19.
It began with a small group of scientists and their graduate students at the University of Oxford, who were joined by colleagues from Bristol University, Diamond Light Source and academics in France, Italy, and Spain – all working from home but coming together weekly on Zoom to tackle this terrifying disease.
Thus began an international collaboration involving 29 scientists around the world focused on understanding how SARS-COV-2 makes its worker proteins at the molecular level so we could develop novel antiviral drugs and block their production. Read the full story.
Professor Charlotte Deane elected Fellow of the Royal Society
Professor Charlotte Deane MBE, Professor of Structural Bioinformatics in Oxford’s Department of Statistics, has today been announced among the new Fellows of the Royal Society.
OpenBind releases first open dataset and AI model for drug discovery
The OpenBind consortium’s first release of experimental data marks a milestone in efforts to improve how artificial intelligence (AI) is used in drug discovery.
Oxford statisticians take part in PKU–Oxford conference on quantitative finance and data science
Researchers from the University of Oxford’s Department of Statistics were among those taking part in a joint conference with Peking University in April, bringing together academics working across quantitative finance, data science and related areas.